Cited 10 times in
Impact of Susceptibility to Injectable Antibiotics on the Treatment Outcomes of Mycobacterium abscessus Pulmonary Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강영애 | - |
dc.contributor.author | 박영목 | - |
dc.date.accessioned | 2021-09-29T01:48:16Z | - |
dc.date.available | 2021-09-29T01:48:16Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184554 | - |
dc.description.abstract | Background: Current guidelines recommend a susceptibility-based regimen for Mycobacterium abscessus subspecies abscessus pulmonary disease (MAB-PD), but the evidence is weak. We aimed to investigate the association between treatment outcomes and in vitro drug susceptibility to injectable antibiotics in MAB-PD patients. Methods: We enrolled MAB-PD patients treated with intravenous amikacin and beta-lactams for ≥4 weeks at 4 referral hospitals in Seoul, South Korea. Culture conversion and microbiological cure at 1 year were evaluated based on susceptibility to injectable antibiotics among patients treated with those antibiotics for ≥2 weeks. Results: A total of 82 patients were analyzed. The mean age was 58.7 years, and 65.9% were women. Sputum culture conversion and microbiological cure were achieved in 52.4% and 41.5% of patients, respectively. Amikacin was the most common agent to which the M. abscessus subspecies abscessus isolates were susceptible (81.7%); 9.8% and 24.0% of the isolates were resistant to cefoxitin and imipenem, respectively. The clarithromycin-inducible resistance (IR) group (n = 65) had a lower microbiological cure rate than the clarithromycin-susceptible group (35.4% vs 64.7%). The treatment outcomes appeared to be similar regardless of in vitro susceptibility results with regard to intravenous amikacin, cefoxitin, imipenem, and moxifloxacin. In the subgroup analysis of the clarithromycin-IR group, the treatment outcomes did not differ according to antibiotic susceptibility. Conclusions: We did not find evidence supporting the use of susceptibility-based treatment with intravenous amikacin and beta-lactams in patients with MAB-PD. Further research is required. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | OPEN FORUM INFECTIOUS DISEASES | - |
dc.publisher | OPEN FORUM INFECTIOUS DISEASES | - |
dc.relation.isPartOf | OPEN FORUM INFECTIOUS DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Impact of Susceptibility to Injectable Antibiotics on the Treatment Outcomes of Mycobacterium abscessus Pulmonary Disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Youngmok Park | - |
dc.contributor.googleauthor | Yea Eun Park | - |
dc.contributor.googleauthor | Byung Woo Jhun | - |
dc.contributor.googleauthor | Jimyung Park | - |
dc.contributor.googleauthor | Nakwon Kwak | - |
dc.contributor.googleauthor | Kyung-Wook Jo | - |
dc.contributor.googleauthor | Jae-Joon Yim | - |
dc.contributor.googleauthor | Tae Sun Shim | - |
dc.contributor.googleauthor | Young Ae Kang | - |
dc.identifier.doi | 10.1093/ofid/ofab215 | - |
dc.contributor.localId | A00057 | - |
dc.contributor.localId | A05828 | - |
dc.relation.journalcode | J03621 | - |
dc.identifier.eissn | 2328-8957 | - |
dc.identifier.pmid | 34189168 | - |
dc.subject.keyword | Mycobacterium abscessus | - |
dc.subject.keyword | amikacin | - |
dc.subject.keyword | beta-lactams | - |
dc.subject.keyword | microbial sensitivity tests | - |
dc.subject.keyword | nontuberculous mycobacteria | - |
dc.subject.keyword | treatment outcome | - |
dc.contributor.alternativeName | Kang, Young Ae | - |
dc.contributor.affiliatedAuthor | 강영애 | - |
dc.contributor.affiliatedAuthor | 박영목 | - |
dc.citation.volume | 8 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | ofab215 | - |
dc.identifier.bibliographicCitation | OPEN FORUM INFECTIOUS DISEASES, Vol.8(6) : ofab215, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.